Therefore, substantial revenue opportunity for conventional disease-modifying antirheumatic drugs (DMARDs) remains in early lines of therapy.
因此,在早期治疗中,常规抗风湿性关节炎疾病缓解用药还有很大市场。
2
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
In recent years, biologic disease-modifying anti-rheumatic drugs (DMARDs) have been introduced that can help to modify this irregular immune response and improve symptoms of the disease.